A previous study by our group using dendritic cells (DC) pulsed ex vivo with the lysate of the HepG2 cell line showed evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma (HCC).
The ImmunoTACE trial evaluated the preliminary activity of this vaccine in combination with transarterial chemoembolisation (TACE) in patients with intermediate stage HCC.
